Human Insulin Size, Product Launch, Major Companies, Revenue Analysis, Till 2028

Comments · 27 Views

The global insulin market size was USD 26.80 Billion in 2020 and is expected to register a CAGR of 4.2% during the forecast period.

The global Human Insulin market size is expected to reach USD 26.80 billion in 2028 at a CAGR of 4.2% during the forecast period, according to the latest report by Reports and Data. Increasing prevalence of diabetes and obesity across the globe, rising dependency on Human Insulin therapy, and rapid technological advancements in Human Insulin delivery devices are some key factors expected to drive demand for Human Insulin and fuel market revenue growth over the forecast period. In addition, development of newer injectable formulations of Human Insulin, growing popularity of Human Insulin pumps and pens, and increasing collaborations among key companies to develop Human Insulin analogs are other major factors expected to contribute to revenue growth of the market going ahead.

Human Insulin is a peptide hormone comprising 51 amino acids and is secreted by islets of Langerhans of pancreas. Human Insulin facilitates normal uptake of glucose in blood by binding to the receptors on plasma membranes of the cells to regulate blood glucose levels. Human Insulin is categorized into three types including short-acting, intermediate-acting, and long-acting Human Insulin depending on its duration of the action. Human Insulin is often administrated through subcutaneous, intravenous, and intramuscular routes and is widely used in hospitals to manage hyperglycemia. Human Insulin is the most effective treatment of diabetes and increasing employment of Human Insulin therapy to treat diabetes is another key factor expected to drive market growth over the forecast period. Advancements in recombinant DNA technologies have enabled the development of analogs to human Human Insulin to boost effectiveness of Human Insulin to regulate blood glucose levels without causing adverse effects.

Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/2338

Increasing research activities to develop Human Insulin analogs and optimize Human Insulin therapy is expected to continue to drive market growth. Human Insulin plays a crucial role in regulation of metabolism, and over the recent past, extensive research activities have been carried out to understand its role in various physiological processes. However, adverse effects of Human Insulin therapy and increasing incidence of Human Insulin resistance are expected to restrain market growth to a certain extent over the forecast period.

Some Key Highlights from the Report:

  • Basal or long-acting Human Insulin segment is expected to account for a significantly large revenue share over the forecast period, attributable to increasing use of basal analogs to treat diabetes, for improving glycemic control in patients with problematic hypoglycemia, and can be easily used in different Human Insulin regimens.
  • Type 1 diabetes segment is expected to register significant revenue growth over the forecast period, attributable to increasing incidence of type 1 diabetes, rising adoption of Human Insulin injections for better management of type 1 diabetes, and availability of various Human Insulin regimens and strategies.
  • Pens segment revenue is expected to expand at a rapid revenue CAGR over the forecast period, attributable to increasing adoption of Human Insulin pens for self-management of diabetes, advancements in Human Insulin pens and introduction of smart Human Insulin pens, and availability of cost-effective disposable and reusable Human Insulin pens.
  • Clinics segment is expected to account for a considerable revenue share in the global market over the forecast period, attributable to increasing number of diabetes clinics across the globe, presence of skilled professionals and nurses, and availability of advanced facilities at affordable prices.
  • North America is expected to dominate other regional market in terms of revenue share over the forecast period, attributable to high prevalence of diabetes and obesity due to unhealthy lifestyles and genetic conditions, increasing RD activities to develop better treatment approaches for diabetes management, and presence of key players in the region.

  Research Methodology:

Reports and Data utilizes a unique approach to research to offer a comprehensive overview of the global Human Insulin Market to offer insights into investment opportunities for stakeholders, investors, clients, and businesses to make informed decisions. The report includes SWOT analysis, Porter’s Five Forces analysis, feasibility analysis, and investment return analysis to offer a better understanding of the market scenario.

Inquiry Before Buying @ https://www.reportsanddata.com/inquiry-before-buying/2338

Asia Pacific is expected to lead the market growth over the coming years owing to rapid advancements in the healthcare sector in APAC countries such as India, China, and Japan. North America is anticipated to register the highest market growth over the forecast period attributed to the increasing availability of robust healthcare and clinical settings, legalization of medical marijuana, favorable reimbursement scenario, presence of key market players, and rapid technological advancements in the region.

The growing popularity of over-the-counter medications driving market growth

Growing incidence of acute and chronic diseases and lesser access to advanced medical facilities owing to low disposable income levels are driving the demand for over-the-counter medications. Availability of generic and low-cost alternatives to medical therapies are some other factors playing a major role in driving demand for over-the-counter medications.

Restriction on product launches and RD activities to hamper the market growth

The imposition of strict government regulations and shortage of funds has put a halt on product launches and RD activities and is expected to restrain market growth over the forecast period. In addition, the launch of expensive drugs and therapies and increasing regulations regarding safety and approvals are also hampering the market growth.

  Competitive Landscape:

The global market comprises various market players operating at regional and global levels. These key players are adopting various strategies such as RD investments, license agreements, partnerships, mergers and acquisitions, collaborations, and joint ventures to gain a robust footing in the market.

Top Companies Profiled in the Report:

  • Novo Nordisk A/S
  • Sanofi
  • Eli Lily and Company
  • ADOCIA
  • Julphar
  • Pfizer, Inc.
  • Oramed Pharmaceuticals, Inc.
  • Bristol-Myers Squibb Company
  • Merck Co., Inc.
  • GlaxoSmithKline Plc.

  Human Insulin Market Segmentation:

Product Type Outlook:

  • Basal or Long-Acting Human Insulin
  • Bolus or Fast-Acting Human Insulin
  • Traditional Human Human Insulin
  • Combination Human Insulin
  • Biosimilar Human Insulin

Diseases Outlook:

  • Type 1 Diabetes
  • Type 2 Diabetes
  • Gestational Diabetes
  • Prediabetes

Delivery Devices Outlook:

  • Syringes
  • Pens
  • Pumps
  • Others

End-Use Outlook:

  • Home healthcare
  • Hospitals
  • Over the counter (OTC)
  • Clinics
  • Others

Regional Outlook:

  • North America (U.S., Canada, Mexico)
  • Europe (Germany, U.K., Italy, France, BENELUX, Rest of Europe)
  • Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
  • Latin America (Brazil, Rest of LATAM)
  • Middle East Africa (Saudi Arabia, U.A.E., South Africa, Rest of the Middle East Africa)

  Frequently asked questions addressed in the report:

  • What is the revenue growth rate of the global Human Insulin market over the forecast period?
  • What are the major factors driving the growth of the Global Human Insulin Market?
  • What are the key challenges impacting the global Human Insulin market growth?
  • What are the outcomes of the SWOT Analysis and Porter’s Five Forces Analysis conducted in the report?

Request customization on the report @ https://www.reportsanddata.com/request-customization-form/2338

Thank you for reading our report. For more details please connect with us and our team will ensure the report is customized to meet all the needs of clients. The report also offers a comprehensive regional analysis and specific countries can be included in the report according to the requirements.

Explore Latest Trending Research Reports By Reports and Data:

Synthetic Biology Market @ https://www.reportsanddata.com/report-detail/synthetic-biology-market

Diabetic Retinopathy Market @ https://www.reportsanddata.com/report-detail/diabetic-retinopathy-market

Audiology Devices Market @ https://www.reportsanddata.com/report-detail/audiology-devices-market

Manual Resuscitators Market @ https://www.reportsanddata.com/report-detail/manual-resuscitators-market

 

  About Reports and Data

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.

Contact Us:

John W
Head of Business Development
Reports And Data | Web: www.reportsanddata.com
Direct Line: +1-212-710-1370
E-mail: sales@reportsanddata.com
LinkedIn | Twitter | Blogs

Comments